Tips

九月美迪西将主办2场线上直播，同时参与15场海内外行业会议，期待与各位业内同仁交流分享药物研发新趋势。

第十二届药物毒理学年会

由中国药理学会药物毒理专业委员会主办的“第十二届药物毒理学年会”将于2024年9月1日至3日在上海市光大会展中心召开。

为推动毒理学前沿研究进展和成果转化，美迪西专家将从一般毒理学、先进治疗药物、药物GLP规范与质量保证等研究方向，在相应主题分会场带来3场精彩演讲，同时展出1项研究壁报，希望通过此次重要的毒理学术盛会，与行业专家深入交流和分享最新的研究成果。

EFMC-ISMC 2024

The XXVIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2024) is organised by the Medicinal Chemistry Division of Italian Chemical Society, on behalf of the European Federation for Medicinal chemistry and Chemical biology (EFMC). The symposium will take place in Rome, Italy from September 1-5, 2024. The EFMC is the main organisation for the European Medicinal Chemistry and Chemical Biology community, with 30 member societies and about 9.000 members. Its biennial EFMC-ISMC is a key symposium in the field of medicinal chemistry and drug discovery, and it traditionally attracts around 1.000 participants both from industry and academia. The scientific programme of EFMC-ISMC 2024 will furthermore cover a wide range of selected topics with parallel sessions split into three main themes: 1) Chemical Biology; 2) Drug Discovery Pojects; 3) Technologies.

Medicilon is thrilled to exhibit in the conference. Dr. Paul van Stralen, VP of Strategic Collaborations EMEA at , will be available throughout the conference. We invite you to visit us at Medicilon Booth #6 to explore our services and capabilities.

EUROTOX 2024

We are pleased to announce that Medicilon will exhibit in the EUROTOX 2024 with the Booth #43. The congress will take place from 8 to 11 September 2024 at Copenhagen, Denmark. The congress theme “Toxicology - A Quest for safe Chemicals and Medicines” reflects the congress programme including a variety of topics dealing with safety of drugs and environmental chemicals, new and emerging technologies, personalised medicine, human health effects caused by exposure to chemicals as well as safety issues arising from climate changes. Dr. Renzong Xie, Vice President of Medicilon Quality Assurance Department, and Medicilon team will be present throughout the conference. Please stop by at our booth and discuss how Medicilon’s services and capabilities could support your research needs and expedite your drug discovery and development process.

PBSS Workshop

The landscape of disease-treatment modalities has undergone a dramatic transformation in recent years. New therapeutic modalities, with innovative mechanisms of action, are revolutionizing patient care. Some of these advancements extend beyond traditional small molecules and antibodies to encompass exciting areas like bispecific antibodies, ADCs and gene therapies. Even within the small molecule realm, covalent binders, biased agonists and pan-inhibitors are pushing the boundaries of our understanding of pharmacokinetic (PK)/pharmacodynamic (PD) relationships. In addition to this, therapeutics that are intended for ocular and neuro delivery put forth challenges associated with delivering desired drug concentrations at the site of action. Medicilon team will be present throughout the event.

2024香港国际生物科技论坛展览 

BIOHK 2024第三届香港国际生物科技论坛暨展会作为香港生物科技展会的标杆展会，将于9月11-14在香港会展中心召开。

美迪西团队将在3E-C10号展位等待业界同仁的光临！

2024第三届国际生物医药产业发展大会 

以“增进跨文化创新，保障世界永续健康”为主题的第三届国际生物医药产业发展大会，将于2024年9月12-14日在上海举办。

❖ 美迪西首席科学馆彭双清教授将担任美迪西英才“山海会”圆桌论坛主持人，并参与高端对话环节；

❖ 美迪西制剂部高级主任&新药注册部总监王丹博士将出席发表演讲；

❖ 美迪西药效部项目经理袁云云博士将出席发表演讲。

2024 Biosespark Annual Conference

Biosespark will host the 2024 Annual Conference on Saturday, September 14 at Cambridge, MA. The conference theme this year is “Braving through the Winter of Biotech”, and will bring together professionals from the biotech industry to discuss the latest trends and innovations. Whether you're a seasoned expert or just starting out in the field, this event is perfect for anyone looking to stay ahead in the world of biotechnology. Medicilon is excited to attend and exhibit at the conference. Dr. Qingcong Lin, President of Medicilon USA Corp., will give a presentation. Dr. Lin brings nearly 40 years of experience in pharmaceutical R&D, making significant contributions to both academia and the global industry. Medicilon team will be present throughout the event. 

26th North American ISSX and 39th JSSX Meeting

Meet Medicilon at 26th North American ISSX and 39th JSSX Meeting. As the foremost organization representing the interests of researchers and educators in DMPK and other related areas of research, the International Society for the Study of Xenobiotics (ISSX) is engaged in multiple activities to support, promote, and advance the science worldwide.  ISSX has an international base of members from more than 45 countries. Members are comprised fairly evenly between academic and industry groups and consist primarily of research scientists and future scientists in toxicology, pharmacology, molecular biology, and other disciplines related to the study of xenobiotics. 

During the Conference, Dr. Pin Jiang, Senior Director of DMPK at Medicilon, will present the poster titled "Enhancing Drug-Drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4". Medicilon team will be present throughout the event. 

第八届全国核酸疫苗大会

中国疫苗行业协会核酸疫苗分会将于2024年9月19日-22日在上海举办第八届全国核酸疫苗大会。本次大会的主题为“砥砺深耕 ·笃行致远”，热情邀请全国相关领域专家、学者、科研骨干、企业代表与会交流。

美迪西团队将在A02号展位等待业界同仁的光临！

PBSS Workshop

With the advent of complex biologics and the increasing use of novel modalities over traditional antibodies during drug development, it has become critical to develop our understanding on their unique safety assessments and challenges. The intent of this workshop is to enlighten to develop an understanding of toxicity risk assessments and share latest progress in the field of biologics to activate discussions that will lead to more successful IND/BLA submissions. Medicilon team will be present throughout the event.

BioForward 2024

Meet Medicilon at BioForward 2024! BioForward is OBN's 'Roadmap for Growth' Life Sciences event, designed to provide the support, skills, know-how and industry connections required to catalyse the growth of your company. Now in its sixth year, BioForward is attended by leaders and decision makers of growing R&D companies across all therapy and technological areas, alongside companies who provide the specialist services, products, advice and expertise essential for all companies as they grow. Medicilon is excited to attend and exhibit at the conference. Dr. Wenjie Li, Vice President of the CMC Unit at Medicilon, PARTNERING WITH THE RIGHT MANUFACTURER TO ACCELERATE YOUR RESEARCH" at 14:35-14:55 local time during Workshop Session 6 - Partnering with the right manufacturer to accelerate your research.

第九届国际药物研究与发展新兴技术大会（IAPC-9）

IAPC-9由国际物理化学家协会、ADMET 和 DMPK Journal 主办，北京大学药学院、上海交通大学药学院、美迪西和腾迈联新联合主办。此次会议的中心主题是“药物发现和开发的新兴技术”，旨在传播和分享药物发现和开发领域的新技术和前沿平台。

美迪西作为本次大会的协办单位，将全程在展位等待业界同仁的光临！

第三届BIONNOVA北京创新论坛

时维九月，春华秋实，第三届BIONNOVA北京创新论坛将于朗丽兹西山花园酒店开启全新篇章！

美迪西首席科学官彭双清教授将出席发表演讲，同时美迪西团队将全程设展，期待与 您再次相会！

2024 SAPA Annual Conference

Sino-American Pharmaceutical Professionals Association (SAPA) will host the 2024 Annual Conference on Friday & Saturday, September 27 & 28 at Hyatt Regency New Brunswick, 2 Albany St, New Brunswick, New Jersey. The conference theme this year is “Redefining Medicine: Navigating Resilience, Transforming Lives”, and will include plenary sessions and 7 panel discussions such as Investment/Business Development, Drug Discovery, CMC, Clinical Development/Regulatory, Career Development, Executive/Legal, Artificial Intelligence (AI), and plenty of networking opportunities.  During the SAPA SAPA Annual Conference, Dr. Wenjie Li, Vice President of the CMC Unit at Medicilon, will participate in the panel discussion "CMC and Outsourcing". Dr. Qingcong Lin, President of Medicilon USA Corp., and Medicilon team will be present throughout the conference. 

DOT 2024

Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules. DOT 2024 four-day event brings back popular topics like kinases, immunomodulation, and degraders, plus new coverage of covalent chemistries and induced proximity, synthetic biology, cancer antibodies, generative AI, and translational models. We looks forward to meeting you from September 30-October 3 in Boston, MA. Medicilon is experienced with oncology drug in any preclinical phases, from hit-to-lead to IND. We provide integrated service strategies for sponsors’ oncology drug discovery and development pipelines. We aim to enhance every step in preclinical search and to deliver real time data.

marketing@hangzhouaijunshengwu.com媒体与会务请联系
美迪西市场部微信或邮箱